Holen Sie sich die Stockscreener-App
2.60
0.39%
0.01
Handel nachbörslich:
2.58
-0.02
-0.77%
Schlusskurs vom Vortag:
$2.59
Offen:
$2.5
24-Stunden-Volumen:
456.49K
Relative Volume:
0.68
Marktkapitalisierung:
$202.88M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
52.00
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+0.78%
1M Leistung:
+12.55%
6M Leistung:
+157.43%
1J Leistung:
+109.68%
1-Tages-Spanne:
$2.46
$2.60
1-Wochen-Bereich:
$2.43
$2.62
52-Wochen-Spanne:
$0.8214
$2.76
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.60 | 202.88M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news
Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st
Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Nasdaq
Exclusive Access: Protalix BioTherapeutics Reveals Growth Strategy at Premium Investor Summit - Stock Titan
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive financial news
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive Investors USA
FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA
Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news
Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey
PLX: 2024 Results - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada
Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com
Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz
Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com
StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow
Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan
Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter
Protalix Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Y Intercept Hong Kong Ltd Acquires Shares of 18,818 Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum - Proactive financial news
Protalix BioTherapeutics Inc (PLX) Worth Considering For The Next Few Weeks - Stocks Register
H.C. Wainwright reiterates Protalix BioTherapeutics Inc (PLX) rating to a Buy - Knox Daily
Research Analysts Set Expectations for PLX FY2025 Earnings - MarketBeat
Q1 Earnings Forecast for PLX Issued By HC Wainwright - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Insider’s View: Deciphering Protalix BioTherapeutics Inc (PLX)’s Financial Health Through Ratios - The Dwinnex
Was Protalix BioTherapeutics Inc (PLX)’s session last reading good? - US Post News
What is HC Wainwright’s Forecast for PLX FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for PLX FY2024 Earnings? - MarketBeat
H.C. Wainwright lifts Protalix stock target to $15, maintains buy - MSN
Research Analysts Issue Forecasts for PLX Q1 Earnings - Defense World
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):